NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.580
-0.040 (-2.47%)
At close: Aug 1, 2025, 4:00 PM
1.620
+0.040 (2.53%)
After-hours: Aug 1, 2025, 8:00 PM EDT

Company Description

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections.

The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.

It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.

In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses.

NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

NanoViricides, Inc.
NanoViricides logo
CountryUnited States
Founded2005
IndustryBiotechnology
SectorHealthcare
Employees7
CEOAnil Diwan

Contact Details

Address:
1 Controls Drive
Shelton, Connecticut 06484
United States
Phone203 937 6137
Websitenanoviricides.com

Stock Details

Ticker SymbolNNVC
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001379006
CUSIP Number630087302
ISIN NumberUS6300873022
Employer ID76-0674577
SIC Code2834

Key Executives

NamePosition
Dr. Anil R. Diwan Ph.D.Executive Chairman, President, Chief Executive Officer and Secretary
Meeta R. Vyas B.S., M.B.A., MBA, SBChief Financial Officer and Compliance Officer
Dr. Randall W. Barton Ph.D.Chief Scientific Officer

Latest SEC Filings

DateTypeTitle
May 15, 202510-QQuarterly Report
Feb 14, 202510-QQuarterly Report
Dec 12, 20248-KCurrent Report
Nov 14, 202410-QQuarterly Report
Oct 15, 2024DEF 14AOther definitive proxy statements
Sep 27, 202410-KAnnual Report
Aug 9, 20248-KCurrent Report
Aug 9, 2024424B5Filing
May 15, 202410-QQuarterly Report
May 13, 2024UPLOADFiling